OBJECTIVE: To identify and compare clinical and neuroimaging predictors of primary lobar intracerebral hemorrhage (ICH) recurrence, assessing their relative contributions to recurrent ICH. METHODS: Subjects were consecutive survivors of primary ICH drawn from a single-center prospective cohort study. Baseline clinical, imaging, and laboratory data were collected. Survivors were followed prospectively for recurrent ICH and intercurrent aspirin and warfarin use, including duration of exposure. Cox proportional hazards models were used to identify predictors of recurrence stratified by ICH location, with aspirin and warfarin exposures as time-dependent variables adjusting for potential confounders. RESULTS: A total of 104 primary lobar ICH survivors were enrolled. Recurrence of lobar ICH was associated with previous ICH before index event (hazard ratio [HR] 7.7, 95% confidence interval [CI] 1.4-15.7), number of lobar microbleeds (HR 2.93 with 2-4 microbleeds present, 95% CI 1.3-4.0; HR = 4.12 when >or=5 microbleeds present, 95% CI 1.6-9.3), and presence of CT-defined white matter hypodensity in the posterior region (HR 4.11, 95% CI 1.01-12.2). Although aspirin after ICH was not associated with lobar ICH recurrence in univariate analyses, in multivariate analyses adjusting for baseline clinical predictors, it independently increased the risk of ICH recurrence (HR 3.95, 95% CI 1.6-8.3, p = 0.021). CONCLUSIONS: Recurrence of lobar ICH is associated with previous microbleeds or macrobleeds and posterior CT white matter hypodensity, which may be markers of severity for underlying cerebral amyloid angiopathy. Use of an antiplatelet agent following lobar ICH may also increase recurrence risk.
OBJECTIVE: To identify and compare clinical and neuroimaging predictors of primary lobar intracerebral hemorrhage (ICH) recurrence, assessing their relative contributions to recurrent ICH. METHODS: Subjects were consecutive survivors of primary ICH drawn from a single-center prospective cohort study. Baseline clinical, imaging, and laboratory data were collected. Survivors were followed prospectively for recurrent ICH and intercurrent aspirin and warfarin use, including duration of exposure. Cox proportional hazards models were used to identify predictors of recurrence stratified by ICH location, with aspirin and warfarin exposures as time-dependent variables adjusting for potential confounders. RESULTS: A total of 104 primary lobar ICH survivors were enrolled. Recurrence of lobar ICH was associated with previous ICH before index event (hazard ratio [HR] 7.7, 95% confidence interval [CI] 1.4-15.7), number of lobar microbleeds (HR 2.93 with 2-4 microbleeds present, 95% CI 1.3-4.0; HR = 4.12 when >or=5 microbleeds present, 95% CI 1.6-9.3), and presence of CT-defined white matter hypodensity in the posterior region (HR 4.11, 95% CI 1.01-12.2). Although aspirin after ICH was not associated with lobar ICH recurrence in univariate analyses, in multivariate analyses adjusting for baseline clinical predictors, it independently increased the risk of ICH recurrence (HR 3.95, 95% CI 1.6-8.3, p = 0.021). CONCLUSIONS: Recurrence of lobar ICH is associated with previous microbleeds or macrobleeds and posterior CT white matter hypodensity, which may be markers of severity for underlying cerebral amyloid angiopathy. Use of an antiplatelet agent following lobar ICH may also increase recurrence risk.
Authors: S M Greenberg; M E Briggs; B T Hyman; G J Kokoris; C Takis; D S Kanter; C S Kase; M S Pessin Journal: Stroke Date: 1996-08 Impact factor: 7.914
Authors: S M Greenberg; J P Vonsattel; A Z Segal; R I Chiu; A E Clatworthy; A Liao; B T Hyman; G W Rebeck Journal: Neurology Date: 1998-04 Impact factor: 9.910
Authors: Jonathan Rosand; Alona Muzikansky; Ashok Kumar; Jonathan J Wisco; Eric E Smith; Rebecca A Betensky; Steven M Greenberg Journal: Ann Neurol Date: 2005-09 Impact factor: 10.422
Authors: Joseph Broderick; Sander Connolly; Edward Feldmann; Daniel Hanley; Carlos Kase; Derk Krieger; Marc Mayberg; Lewis Morgenstern; Christopher S Ogilvy; Paul Vespa; Mario Zuccarello Journal: Stroke Date: 2007-05-03 Impact factor: 7.914
Authors: Kathryn L Lunetta; Porat M Erlich; Karen T Cuenco; L Adrienne Cupples; Robert C Green; Lindsay A Farrer; Charles Decarli Journal: Alzheimer Dis Assoc Disord Date: 2007 Apr-Jun Impact factor: 2.703
Authors: Jun Ni; Eitan Auriel; Jenelle Jindal; Alison Ayres; Kristin M Schwab; Sergi Martinez-Ramirez; Edip M Gurol; Steven M Greenberg; Anand Viswanathan Journal: Cerebrovasc Dis Date: 2015-04-08 Impact factor: 2.762
Authors: Andreas Charidimou; Gregoire Boulouis; M Edip Gurol; Cenk Ayata; Brian J Bacskai; Matthew P Frosch; Anand Viswanathan; Steven M Greenberg Journal: Brain Date: 2017-07-01 Impact factor: 13.501
Authors: Valerie Valant; Brendan T Keenan; Christopher D Anderson; Joshua M Shulman; William J Devan; Alison M Ayres; Kristin Schwab; Joshua N Goldstein; Anand Viswanathan; Steven M Greenberg; David A Bennett; Philip L De Jager; Jonathan Rosand; Alessandro Biffi Journal: Transl Stroke Res Date: 2012-04-12 Impact factor: 6.829
Authors: Thanakit Pongpitakmetha; Panagiotis Fotiadis; Marco Pasi; Gregoire Boulouis; Li Xiong; Andrew D Warren; Kristin M Schwab; Jonathan Rosand; M Edip Gurol; Steven M Greenberg; Anand Viswanathan; Andreas Charidimou Journal: Neurology Date: 2020-04-13 Impact factor: 9.910